Silo Pharma Inc. (NASDAQ: SILO) announced that its board of directors has authorized a share repurchase program to acquire up to $1 million of the company's common stock. The program allows purchases to occur on the open market, through privately negotiated transactions, or otherwise, in compliance with Securities and Exchange Commission rules and applicable legal requirements. According to the company's quarterly report for the period ended Sept. 30, 2025, Silo Pharma reported 13,318,273 shares of common stock outstanding as of Nov. 13, 2025.
The timing and amount of any repurchases will depend on market conditions and corporate and regulatory limitations. The program does not obligate the company to acquire a specific number of shares and may be suspended or discontinued at its discretion. This strategic move comes as Silo Pharma positions itself as a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company with a therapeutic focus on addressing underserved conditions.
Silo Pharma's portfolio includes innovative programs targeting stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Key programs include SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's research is conducted in collaboration with leading universities and laboratories, positioning it at the intersection of biotechnology and emerging financial technologies.
The share repurchase program represents a significant development for investors and industry observers, as detailed in the full press release available at https://ibn.fm/gU3uZ. Such programs typically signal management's confidence in the company's long-term value and financial stability, potentially affecting shareholder value and market perception. For a developmental-stage biopharmaceutical company operating in both therapeutic development and cryptocurrency treasury management, this move suggests careful capital allocation strategy amid ongoing research and development efforts.
The announcement was distributed through MissionIR, a specialized communications platform within the Dynamic Brand Portfolio that assists IR firms with syndicated content to enhance company visibility. MissionIR provides access to wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release services, social media distribution, and tailored corporate communications solutions. More information about MissionIR's services is available at https://www.MissionIR.com, with full terms of use and disclaimers accessible at https://www.MissionIR.com/Disclaimer.
For investors tracking Silo Pharma's developments, the latest news and updates relating to SILO remain available in the company's newsroom at https://ibn.fm/SILO. The share repurchase authorization comes at a time when biopharmaceutical companies face increasing pressure to demonstrate both scientific innovation and financial discipline, particularly those operating in niche therapeutic areas with significant unmet medical needs.
